Corticosteroid Therapy Guidelines

Introduction to Risks

Patients with pre-existing conditions (diabetes, osteoporosis, glaucoma, hypertension) are at higher risk for adverse effects from corticosteroid therapy, according to the Annals of the Rheumatic Diseases 1
Long-term corticosteroid use increases the risk of various complications, including osteoporosis, adrenal suppression, metabolic disturbances, cardiovascular effects, and increased infection risk, with preventive measures recommended from the outset of therapy, as suggested by guidelines to minimize risks 2

The American College of Rheumatology recommends preventive measures, including calcium and vitamin D supplementation, for all patients on long-term corticosteroid therapy to reduce fracture risk 1
Calcium supplementation (800-1000 mg daily) and vitamin D (800 IU daily) are recommended for all patients to prevent osteoporosis, along with baseline bone mineral density testing before or within 1 month of starting therapy, and follow-up testing at 1 year, then every 2-3 years if stable, or annually if declining 2
Bisphosphonate therapy is recommended for high-risk patients (T-score ≤-1.5 or FRAX 10-year risk ≥20% for major osteoporotic fracture) to prevent fractures 2
Fracture risk increases within 3 months of starting therapy, highlighting the need for early intervention 2
Higher doses (≥7.5 mg prednisone daily) significantly increase fracture risk, particularly in patients ≥40 years, who are at higher risk than younger patients 3

Adrenal suppression occurs in approximately 50% of patients after withdrawal of medium/high-dose therapy, presenting with weakness, fatigue, nausea, vomiting, and pain that can mimic underlying disease, and requires tapering when discontinuing therapy to prevent withdrawal syndrome 2
Gradual tapering is necessary when discontinuing therapy to prevent adrenal insufficiency, and monitoring for withdrawal symptoms is recommended 2

Regular monitoring of blood glucose and potassium is necessary due to the risk of hypertension, brittle diabetes, and hypokalemia, respectively 2
Prolonged therapy is associated with various complications, including brittle diabetes in 20% of patients requiring treatment withdrawal 4, 5

Long-term corticosteroid use increases the risk of atherosclerosis, a risk factor for aortic aneurysm development, particularly in patients with existing cardiovascular risk factors such as hypertension, diabetes, smoking, and dyslipidemia, as noted by the American College of Cardiology 6
Patients on long-term corticosteroids, especially those with autoimmune disorders, have a higher risk of developing aortic aneurysms, with a mean age of 53.8 years, compared to 71.8 years in non-autoimmune patients, and this risk is further increased by existing cardiovascular risk factors 6, 7
High doses of prednisone (≥7.5 mg daily) increase the risk of aortic complications, as reported by the Pharmacological Research journal 8
The cumulative effect of total prednisone dose correlates with an increased risk of aortic aneurysm development, according to the Annals of the Rheumatic Diseases journal 7
Treatment exceeding 3 months is considered high-risk for aortic complications 8, 9
Using the lowest effective dose of prednisone for the shortest duration possible minimizes exposure and reduces the risk of aortic aneurysm development, as recommended by the Annals of the Rheumatic Diseases journal 7
Regular monitoring of cardiovascular risk factors, including blood pressure and lipid profiles, is essential for patients on long-term corticosteroids, as suggested by the Journal of the American College of Cardiology and the Otolaryngology--head and neck surgery journal 6, 10

Complete immunizations are recommended before starting therapy to prevent infections, and consideration should be given to prophylactic co-trimoxazole for high-risk patients 11, 2
Increased risk of serious infections (hazard ratio 1.57) and mortality risk (hazard ratio 2.14) 12

Implementing preventive strategies from the outset, including regular monitoring and prophylactic medications, is essential to minimize risks associated with long-term corticosteroid therapy, according to the general medical consensus, although not explicitly stated in this article with a citation 1
Using the lowest effective dose for the shortest duration possible is a recommended practice to reduce adverse effects, and is supported by various medical guidelines, including those from the American College of Rheumatology, although not explicitly stated in this article with a citation 1
Regular monitoring of blood pressure, glucose, potassium, and bone density is necessary, along with provision of a steroid card/alert for emergency situations, and consideration of prophylactic medications for osteoporosis 2, 11
Consider bisphosphonates for high fracture risk and monitor for complications regularly, including bone mineral density testing, blood glucose monitoring, blood pressure checks, eye examinations, and growth monitoring in children 9, 13
Regular monitoring for complications and consideration of early use of steroid-sparing agents are recommended to minimize the risks associated with long-term corticosteroid therapy 4, 13

Effective birth control should be used if sexually active, and some medications used to prevent steroid complications (e.g., bisphosphonates) have fetal risks, highlighting the need for careful consideration in pregnant or potentially pregnant patients 3
Inhaled corticosteroids have not been clearly associated with an increased risk of aortic aneurysm development, as reported by the Pharmacological Research journal 8
Posterior subcapsular cataracts with prolonged use 14
Growth suppression, requiring regular monitoring of linear growth in children 4, 15
Surgical management is often required for definitive treatment of aortic aneurysms, particularly with large or symptomatic aneurysms 6
Continued surveillance is necessary for patients who have developed aortic aneurysms while on corticosteroid therapy, as they remain at risk for additional vascular complications 6